EP1056878B1 - Constructions de chromosomes artificiels, contenant des sequences d'acides nucleiques capables de diriger la formation d'un virus recombine - Google Patents

Constructions de chromosomes artificiels, contenant des sequences d'acides nucleiques capables de diriger la formation d'un virus recombine Download PDF

Info

Publication number
EP1056878B1
EP1056878B1 EP99902747A EP99902747A EP1056878B1 EP 1056878 B1 EP1056878 B1 EP 1056878B1 EP 99902747 A EP99902747 A EP 99902747A EP 99902747 A EP99902747 A EP 99902747A EP 1056878 B1 EP1056878 B1 EP 1056878B1
Authority
EP
European Patent Office
Prior art keywords
cell
artificial chromosome
virus
nucleic acid
construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP99902747A
Other languages
German (de)
English (en)
Other versions
EP1056878A1 (fr
Inventor
Brian Horsburgh
Dong Qiang
Francis Tufaro
Jeffrey Ostrove
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medigene Inc
Original Assignee
Medigene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigene Inc filed Critical Medigene Inc
Publication of EP1056878A1 publication Critical patent/EP1056878A1/fr
Application granted granted Critical
Publication of EP1056878B1 publication Critical patent/EP1056878B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16661—Methods of inactivation or attenuation
    • C12N2710/16662—Methods of inactivation or attenuation by genetic engineering

Definitions

  • This invention relates to artificial chromosome constructs containing foreign nucleic acid sequences, such as viral nucleic acid sequences, and methods of using these constructs for therapy and for recombinant virus production.
  • Artificial chromosomes are large, DNA-based vectors that have been used extensively in the construction of DNA libraries for complex genome mapping and analysis. Artificial chromosomes have been derived from yeast (yeast artificial chromosomes: YACs), bacteria (bacterial artificial chromosomes: BACs, and P1-derived artificial chromosomes: PACs), and mammals (mammalian artificial chromosomes: MACs), such as humans (human artificial chromosomes: HACs). These vectors include elements derived from chromosomes that are responsible for replication and maintenance, and are capable of stably maintaining large genomic DNA fragments.
  • Herpes Simplex virus is the prototypic human herpes virus. Despite the fact that HSV is a human pathogen, there has been a great deal of interest in using HSV as a therapeutic agent.
  • the HSV genome has been sequenced, and many HSV mutants have been generated and used specifically in this context.
  • Generation of HSV mutants has been carried out by using drug selection or by co-transfection of cells with plasmid DNA, usually modified by insertion of a marker gene, and intact viral DNA. Mutants are identified by screening for either drug resistance or recombination and expression of the marker gene, or by plaque hybridization.
  • Another method that has been used to generate herpes virus mutants involves the use of cosmid sets that, taken together, contain complete herpes virus genomes.
  • cosmid sets that contain the entire genomes of Pseudorabies virus (PRV), Varicella-Zoster virus (VZV), Herpes Simplex virus (HSV), Cytomegalovirus (CMV), and Epstein-Barr virus (EBV) have been created.
  • PRV Pseudorabies virus
  • VZV Varicella-Zoster virus
  • HSV Herpes Simplex virus
  • CMV Cytomegalovirus
  • EBV Epstein-Barr virus
  • the invention provides artificial chromosome constructs containing herpes simplex virus sequences, that direct formation of a recombinant herpes simplex virus (e.g ., a lytic or a non-lytic virus) upon introduction into a cell and methods of using these artificial chromosome constructs for therapy (e . g ., gene therapy) and recombinant virus production.
  • a recombinant herpes simplex virus e.g ., a lytic or a non-lytic virus
  • the artificial chromosome construct either in the artificial chromosome portion or in the nucleic acid sequence portion, further includes a heterologous nucleic acid sequence that, for example, encodes a therapeutic gene product, such as a growth factor, a hormone, an enzyme, a vaccine antigen, a cytotoxin, an immunomodulatory protein, an antisense RNA molecule, or a ribozyme.
  • the artificial chromosome portion of the construct can be derived from a bacterial artificial chromosome, a P1-derived artificial chromosome, a yeast artificial chromosome, or a mammalian ( e . g ., human) artificial chromosome.
  • the recombinant virus encoded by the nucleic acid sequence included in the artificial chromosome construct is a herpes simplex virus.
  • the invention features a method of producing a recombinant virus in a cell, for example, a cell in a mammal, in which an artificial chromosome construct as described above is introduced into the cell.
  • This method can further involve introducing into the cell an amplicon that is packaged into a recombinant virion upon introduction of the artificial chromosome construct into the cell.
  • the invention also provides a method of introducing a heterologous nucleic acid sequence into a cell, for example, a cell in a mammal, in which an artificial chromosome construct as described above is introduced into the cell.
  • Also included in the invention is a method of killing a cell, for example, a cell in a mammal (e.g. , a cancer cell), in which an artificial chromosome construct as described above is introduced into the cell.
  • a mammal e.g. , a cancer cell
  • an artificial chromosome construct as described above is introduced into the cell.
  • the invention also features a cell having an artificial chromosome construct stably integrated into its genome.
  • the artificial chromosome construct includes a nucleic acid sequence that encodes an HSV genome in which an immediate early gene is mutated or deleted (see below).
  • the invention also includes methods of making these cells.
  • the invention provides many advantages. For example, when bacterial artificial chromosome constructs are employed in the invention, the constructs can be easily and efficiently propagated in bacteria. This is particularly advantageous in the case of constructs including viral genes that would be cytopathic if the constructs were propagated in mammalian cells. This is also advantageous in the manufacturing of recombinant viruses, because large-scale, bacterial culture methods can be used, rather than methods employing mammalian cell culture.
  • An additional advantage of the invention is that, in contrast to cosmid-based systems for virus production (see above), which rely on recombination of several molecules to reconstitute a complete viral genome, an entire viral genome can be contained in a single artificial chromosome construct, providing increased efficiency and genetic stability. As is discussed further below, this is particularly advantageous in the trans packaging of amplicons into recombinant viruses using the methods of the invention.
  • the invention provides artificial chromosome constructs that contain herpes simplex virus nucleic acid sequences.
  • the artificial chromosome constructs also contain heterologous nucleic acid sequences, i . e ., nucleic acid sequences that are not naturally a component of the artificial chromosome or the viral nucleic acid sequences.
  • the artificial chromosome constructs of the invention can be used in methods for producing recombinant viruses in cells in vivo , for example, in therapy methods ( e . g ., gene therapy methods), or in vitro , for example, in recombinant virus production methods or in amplicon packaging.
  • chromosomes into which foreign nucleic acid sequences can be inserted for use in the invention include, for example, bacterial artificial chromosomes (BACs, e.g. , pBeloBAC11 or pBAC108L; see, e . g ., Shizuya et al ., Proc. Natl. Acad. Sci. USA 89(18):8794-8797, 1992; Wang et al ., Biotechniques 23(6):992-994, 1997), P1-based artificial chromosomes (PACs), yeast artificial chromosomes (YACs; see, e.g. , Burke, Genet. Anal. Tech. Appl.
  • BACs bacterial artificial chromosomes
  • PACs P1-based artificial chromosomes
  • YACs yeast artificial chromosomes
  • MACs mammalian artificial chromosomes
  • HACs human artificial chromosomes
  • Viral nucleic acid sequences that can be inserted into artificial chromosomes to generate the artificial chromosome constructs of the invention can be derived from HSV-1 or HSV-2.
  • viral nucleic acid sequences are included in the artificial chromosome constructs of the invention, so that recombinant viruses are produced from the constructs upon introduction into cells.
  • the recombinant virus produced in this manner results in killing of the cell.
  • the virus produced from the artificial chromosome construct can be a virus that kills the cell in which it is produced by, for example, inducing lysis or apoptosis of the cell.
  • the cell is a cancer cell, such as a cancer cell of a nervous-system type tumor, for example, an astrocytoma, oligodendroglioma, meningioma, neurofibroma, glioblastoma, ependymoma, Schwannoma, neurofibrosarcoma, or medulloblastoma cell.
  • a cancer cell such as a cancer cell of a nervous-system type tumor, for example, an astrocytoma, oligodendroglioma, meningioma, neurofibroma, glioblastoma, ependymoma, Schwannoma, neurofibrosarcoma, or medulloblastoma cell.
  • tumor cells that can be killed, pursuant to the present invention, include, for example, melanoma, pancreatic cancer, prostate carcinoma, breast cancer, lung cancer, colon cancer, gastric cancer, fibrosarcoma, squamous cell carcinoma, neurectodermal, thyroid tumor, pituitary tumor, lymphoma, hepatoma, mesothelioma, and epidermoid carcinoma cells.
  • Other therapeutic applications in which killing of a target cell is desirable include, for example, ablation of keratinocytes and epithelial cells responsible for warts, ablation of cells in hyperactive organs ( e . g ., thyroid), ablation of fat cells in obese patients, ablation of benign tumors ( e.g.
  • benign tumors of the thyroid or benign prostatic hypertrophy ablation of growth hormone-producing adenohypophyseal cells to treat acromegaly, ablation of mammotropes to stop the production of prolactin, ablation of ACTH-producing cells to treat Cushing's disease, ablation of epinephrine-producing chromaffin cells of the adrenal medulla to treat pheochromocytoma, and ablation of insulin-producing beta islet cells to treat insulinoma.
  • the artificial chromosome construct also contains a heterologous nucleic acid sequence encoding one or more of, for example, a cytotoxin, an immunomodulatory protein (i . e ., a protein that either enhances or suppresses a host immune response to an antigen), or a tumor antigen.
  • immunomodulatory proteins include, e.g., cytokines ( e .
  • interleukins for example, any of intetleukins 1-15, ⁇ -, ⁇ -, or ⁇ -interferons, tumor necrosis factor, granulocyte macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF), and granulocyte colony stimulating factor (G-CSF)), chemokines (e . g ., neutrophil activating protein (NAP), macrophage chemoattractant and activating factor (MCAF), RANTES, and macrophage inflammatory peptides MIP-1a and MIP-1b), complement components and their receptors, immune system accessory molecules ( e.g. , B7.1 and B7.2), adhesion molecules (e.g.
  • tumor antigens examples include, e . g ., the E6 and E7 antigens of human papillomavirus, EBV-derived proteins (Van der Bruggen et al ., Science 254:1643-1647, 1991), mucins (Livingston et al ., Cur. Opin. Immun. 4(5):624-629, 1992), such as MUC1 (Burchell et al., Int. J. Cancer 44:691-696, 1989), melanoma tyrosinase, and MZ2-E (Van der Bruggen et al., supra ).
  • heterologous nucleic acid sequence can be inserted into either the artificial chromosome portion of the construct or into the viral portion of the construct in any of these examples.
  • a recombinant virus produced upon introduction of an artificial chromosome construct of the invention into a cell, does not kill the cell.
  • These applications include, for example, use of artificial chromosome constructs that contain a heterologous gene encoding a therapeutic gene product, such as a growth factor, a hormone, a vaccine antigen, an antisense RNA molecule, or a ribozyme (see below).
  • These applications also include using artificial chromosome constructs to immunize against a virus encoded by the nucleic acid sequence included in the construct.
  • the virus produced from the artificial chromosome construct is attenuated or mutated so that it does not replicate and/or so that it cannot kill the cell in which it is produced by, for example, inducing lysis or apoptosis of the cell.
  • Numerous appropriate mutant viruses having these characteristics are known and can readily be adapted for use in the invention by those of ordinary skill in the art.
  • the vectors of Geller U.S. Patent No. 5,501,979; WO 90/09441; American Type Culture Collection (ATCC), Rockville, Maryland, ATCC Accession Number 40544), Breakfield (EP 453,242-A1), Speck (WO 96/04395), Preston et al.
  • HSV mutants can be used include HF (ATCC VR-260), MacIntyre (ATCC VR-539), MP (ATCC VR-735); HSV-2 strains G (ATCC VR-724) and MS (ATCC VR-540); as well as mutants having mutations in one or more of the following genes: the immediate early genes ICP0, ICP4, ICP22, ICP27, and ICP47 (U.S. Patent No.
  • genes necessary for viral replication VL9, VL5, VL42, DNA pol, and ICP8; the ⁇ 34.5 gene; the ribonucleotide reductase gene; the VP16 gene ( i . e ., Vmw65, WO 91/02788; WO 96/04395; WO 96/04394); and the gH, gL, gD or gB genes (WO 92/05263, 94/21807, 94/03207).
  • heterologous nucleic acid sequence included in this type of artificial chromosome construct i.e., a construct that results in production of a non-lytic virus upon introduction into a cell
  • the heterologous gene product can be a protein, such as a growth factor (e.g ., brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), VGF, or VEGF), an enzyme, a hormone, or a vaccine antigen.
  • BDNF brain-derived neurotrophic factor
  • NGF nerve growth factor
  • VGF vascular endothelial growth factor
  • VEGF vascular endothelial growth factor
  • Specific examples of protein gene products that can be produced in the invention include, e.g.
  • tyrosine hydroxylase 1, 2, or 3 which can be used in the treatment of Parkinson's disease
  • Nerve Growth Factor e.g. , the NGF ⁇ subunit
  • hypoxanthine-guanine phosphoribosyl transferase which can be used in the treatment of Lesch-Nyhan disease
  • ⁇ -hexosaminidase ⁇ -chain which can be used in the treatment of Tay-Sachs and Sandhoff s diseases
  • HIV Human Immunodeficiency Virus
  • signal transduction enzymes e.g., Protein Kinase C
  • transcription factors e.g., c-fos, NF-K ⁇
  • oncogenes e.g., erbB, erbB-2/neu, and r
  • the therapeutic product can also be an RNA molecule, such as an antisense RNA molecule that, by hybridization interactions, can be used to block expression of a cellular or pathogen mRNA.
  • the RNA molecule can be a ribozyme (e.g., a hammerhead or a hairpin-based ribozyme) designed either to repair a defective cellular RNA, or to destroy an undesired cellular or pathogen-encoded RNA (see, e.g., Sullenger, Chem. Biol. 2(5):249-253, 1995; Czubayko et al ., Gene Ther. 4(9):943-949, 1997; Rossi, Ciba Found. Symp.
  • the components of the artificial chromosome constructs of the invention can be assembled using standard methods.
  • a viral sequence can be inserted into an artificial chromosome by co-transfection of cells with (i) a construct containing the artificial chromosome, flanked by sequences homologous to regions of the viral genome, and (ii) the viral genome, so that recombination takes place in the cells, resulting in production of a recombinant virus including the artificial chromosome.
  • recombinant DNA molecules can be isolated from cells in which an artificial chromosome construct and viral nucleic acid sequences have been co-transfected, leading to production of a recombinant virus by homologous recombination, and the isolated DNA molecule can be manipulated to insert or delete a gene, as desired.
  • Direct cloning methods employing unique sites in the viral genome and the artificial chromosome, can also be used to assemble the components of the artificial chromosome constructs of the invention.
  • an artificial chromosome into which viral or heterologous nucleic acid sequences are inserted will vary depending, for example, on whether disruption of a particular viral function is desired. For example, if it is desired that the artificial chromosome construct includes viral sequences that will not lead to the production of replicable virus in cells (see above), then the artificial chromosome and the viral sequences can be combined so that a nucleic acid sequence that is essential for viral replication is disrupted. Similarly, insertion of a heterologous nucleic acid sequence can be used to disrupt an essential viral gene. Examples of essential genes in HSV, for example, are described above.
  • the artificial chromosome construct include viral sequences that will lead to the production of a replicable virus in cells (see above).
  • recombination between the artificial chromosome and the viral nucleic acid sequence to generate an artificial chromosome construct can be carried out in a non-essential region of the virus genome.
  • such an insertion can be in the thymidine kinase gene (UL23, see below; this insertion can be made alone or in combination with another insertion), in any one or more of the following genes: RL1, RL2 ( i .
  • the locus encoding latency associated transcripts UL2 (the uracil-DNA glycosylase gene), UL3, UL4, UL10, UL11, UL13, UL16, UL20, UL24, UL40 (the small subunit of ribonucleotide reductase), UL41 (virion host shutoff factor), UL43, UL44, UL45, UL46, UL47, UL50, UL55, UL56, US1 (IE68), US2, US3 (the protein kinase gene), US4 (the glycoprotein G gene), US5, US7 (the glycoprotein I gene), US8 (the glycoprotein E gene), US9, US10, US11, and US 12 (IE12), or in an intergenic sequence.
  • UL2 the uracil-DNA glycosylase gene
  • a heterologous nucleic acid sequence can be.inserted into an artificial chromosome construct in a location that renders it under the control of a regulatory sequence of the artificial chromosome or viral nucleic acid sequences.
  • the heterologous nucleic acid sequence can be inserted as part of an expression cassette that includes regulatory elements, such as promoters or enhancers.
  • regulatory elements can be selected by one of ordinary skill in the art based on, for example, the desired tissue-specificity and level of expression. For example, a cell-type specific or tumor-specific promoter can be used to limit expression of a gene product to a specific cell type.
  • cytotoxic, immunomodulatory, or tumor antigenic gene product is being produced in a tumor cell in order to facilitate its destruction.
  • tissue-specific promoters local administration of an artificial chromosome construct can result in localized expression.
  • non-tissue specific promoters examples include the early Cytomegalovirus (CMV) promoter (U.S. Patent No. 4,168,062) and the Rous Sarcoma Virus promoter (Norton et al ., Molec. Cell Biol. 5:281,1985).
  • CMV Cytomegalovirus
  • HSV promoters such as HSV-1 IE and IE 4/5 promoters, can be used.
  • tissue-specific promoters examples include, for example, the desmin promoter, which is specific for muscle cells (Li et al ., Gene 78:243,1989; Li et al ., J. Biol. Chem. 266:6562, 1991; Li et al ., J. Biol. Chem. 268:10403, 1993); the enolase promoter, which is specific for neurons (Forss-Petter et al ., J. Neuroscience Res. 16(1):141-156, 1986); the ⁇ -globin promoter, which is specific for erythroid cells (Townes et al ., EMBO J.
  • tau-globin promoter which is also specific for erythroid cells (Brinster et al ., Nature 283:499,1980); the growth hormone promoter, which is specific for pituitary cells (Behringer et al ., Genes Dev. 2:453, 1988); the insulin promoter, which is specific for pancreatic beta cells (Selden et al ., Nature 321:545, 1986); the glial fibrillary acidic protein promoter, which is specific for astrocytes (Brenner et al ., J. Neurosci.
  • the tyrosine hydroxylase promoter which is specific for catecholaminergic neurons (Kim et al ., J. Biol. Chem. 268:15689, 1993); the amyloid precursor protein promoter, which is specific for neurons (Salbaum et al ., EMBO J. 7:2807, 1988); the dopamine ⁇ -hydroxylase promoter, which is specific for noradrenergic and adrenergic neurons (Hoyle et al ., J. Neurosci. 14:2455, 1994); the tryptophan hydroxylase promoter, which is specific for serotonin/pineal gland cells (Boularand et al ., J. Biol. Chem.
  • choline acetyltransferase promoter which is specific for cholinergic neurons
  • AADC aromatic L-amino acid decarboxylase
  • proenkephalin promoter which is specific for neuronal/spermatogenic epididymal cells
  • promoters that function specifically in tumor cells include the stromelysin 3 promoter, which is specific for breast cancer cells (Basset et al., Nature 348:699, 1990); the surfactant protein A promoter, which is specific for non-small cell lung cancer cells (Smith et al ., Hum. Gene Ther. 5:29-35, 1994); the secretory leukoprotease inhibitor (SLPI) promoter, which is specific for SLPI-expressing carcinomas (Garver et al ., Gene Ther.
  • stromelysin 3 promoter which is specific for breast cancer cells
  • the surfactant protein A promoter which is specific for non-small cell lung cancer cells
  • SLPI secretory leukoprotease inhibitor
  • tyrosinase promoter which is specific for melanoma cells
  • the stress inducible grp78/BiP promoter which is specific for fibrosarcoma/tumorigenic cells
  • the AP2 adipose enhancer which is specific for adipocytes (Graves, J. Cell. Biochem.
  • the ⁇ -1 antitrypsin transthyretin promoter which is specific for hepatocytes (Grayson et al., Science 239:786, 1988); the interleukin-10 promoter, which is specific for glioblastoma multiform cells (Nitta et al., Brain Res. 649:122, 1994); the c-erbB-2 promoter, which is specific for pancreatic, breast, gastric, ovarian, and non-small cell lung cells (Harris et al ., Gene Ther. 1:170, 1994); the ⁇ -B-crystallin/heat shock protein 27 promoter, which is specific for brain tumor cells (Aoyama et al ., Int. J.
  • the basic fibroblast growth factor promoter which is specific for glioma and meningioma cells (Shibata et al ., Growth Fact. 4:277, 1991); the Epidermal Growth Factor Receptor promoter, which is specific for squamous cell carcinoma, glioma, and breast tumor cells (Ishii et al ., Proc. Natl. Acad. Sci. USA 90:282, 1993); the mucin-like glycoprotein (DF3, MUC1) promoter, which is specific for breast carcinoma cells (Abe et al ., Proc. Natl. Acad. Sci.
  • the mts1 promoter which is specific for metastatic tumors (Tulchinsky et al ., Proc. Natl. Acad. Sci. USA 89:9146, 1992); the NSE promoter, which is specific for small-cell lung cancer cells (Forss-Petter et al., Neuron 5:187, 1990); the somatostatin receptor promoter, which is specific for small cell lung cancer cells (Bombardieri et al ., Eur. J. Cancer 31A:184, 1995; Koh et al ., Int. J.
  • c-erbB-3 and c-erbB-2 promoters which are specific for breast cancer cells (Quin et al ., Histopathology 25:247, 1994); the c-erbB4 promoter, which is specific for breast and gastric cancer cells (Rajkumar et al ., Breast Cancer Res. Trends 29:3, 1994); the thyroglobulin promoter, which is specific for thyroid carcinoma cells (Mariotti et al ., J. Clin. Endocrinol. Meth. 80:468, 1995); the ⁇ -fetoprotein promoter, which is specific for hepatoma cells (Zuibel et al ., J. Cell. Phys.
  • villin promoter which is specific for gastric cancer cells (Osborn et al., Virchows Arch. A. Pathol. Anat. Histopathol. 413:303, 1988); and the albumin promoter, which is specific for hepatoma cells (Huber, Proc. Natl. Acad. Sci. USA 88:8099,1991).
  • the artificial chromosome constructs of the invention can be used in in vivo methods, for example, to introduce a therapeutic gene product into a cell, or to kill a cell, either directly or indirectly, through a lytic viral intermediate.
  • the artificial chromosome constructs can be administered by any conventional route used in medicine.
  • an artificial chromosome construct of the invention can be administered directly into the tissue in which an effect, e . g ., expression, is desired, for example, by direct injection or by surgical methods ( e . g ., stereotactic injection into a brain tumor; Pellegrino et al., Methods in Psychobiology (Academic Press, New York, New York, 67-90, 1971)).
  • the construct can be administered via a parenteral route, e . g ., by an intravenous, subcutaneous, intraperitoneal, intradermal, intraepidermal, or intramuscular route, or via a mucosal surface, e.g. , an ocular, intranasal, pulmonary, oral, intestinal, rectal, vaginal, or urinary tract surface.
  • a parenteral route e.g ., by an intravenous, subcutaneous, intraperitoneal, intradermal, intraepidermal, or intramuscular route
  • a mucosal surface e.g. , an ocular, intranasal, pulmonary, oral, intestinal, rectal, vaginal, or urinary tract surface.
  • An artificial chromosome construct formulated in association with bupivacaine is advantageously administered into muscle tissue.
  • the formulation can be advantageously injected via intravenous, intranasal (aerosolization), intramuscular, intradermal, or subcutaneous routes.
  • a neutral or anionic liposome or a cationic lipid such as DOTMA or DC-Chol (see below)
  • the formulation can be advantageously injected via intravenous, intranasal (aerosolization), intramuscular, intradermal, or subcutaneous routes.
  • An artificial chromosome construct in a naked form can advantageously be administered via intramuscular, intradermal, or subcutaneous routes.
  • any of a number of well known formulations for introducing nucleic acid molecules into cells in mammals can be used in the invention.
  • the artificial chromosome constructs can be used in a naked form, free of any packaging or delivery vehicle.
  • the artificial chromosome constructs can be simply diluted in a physiologically acceptable solution, such as sterile saline or sterile buffered saline, with or without a carrier.
  • Artificial chromosome constructs can also be administered in calcium phosphate solutions.
  • the artificial chromosome constructs can be also associated with agents that facilitate cellular uptake of nucleic acid molecules.
  • the artificial chromosome constructs can be complemented with a chemical agent that modifies cellular permeability, such as bupivacaine (see, e . g ., WO 94/16737), encapsulated into a liposome, or associated with cationic lipids or silica, gold, or tungsten microparticles.
  • Liposomes A Practical Approach, RPC New Ed, IRL press (1990), for a detailed description of methods for making liposomes
  • Cationic lipids are also well known and are commonly used for gene delivery.
  • Such lipids include Lipofectin TM , also known as DOTMA (N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride), DOTAP (1,2-bis(oleyloxy)-3-(trimethylammonio)propane), DDAB (dimethyldioctadecylammonium bromide), DOGS (dioctadecylamidologlycyl spermine) and cholesterol derivatives, such as DC-Chol (3 beta-(N-(N',N-dimethyl aminomethane)-carbamoyl) cholesterol).
  • DC-Chol beta-(N-(N',N-dimethyl aminomethane)-carbamoyl) cholesterol
  • Cationic lipids for gene delivery are preferably used in association with a neutral lipid, such as DOPE (dioleyl phosphatidylethanolamine), as, for example, described in WO 90/11092.
  • DOPE dioleyl phosphatidylethanolamine
  • transfection-facilitating compounds can be added to formulations containing cationic liposomes.
  • a number of these compounds are described in, e . g ., WO 93/18759, WO 93/19768, WO 94/25608, and WO 95/2397. They include, e . g ., spermine derivatives useful for facilitating the transport of DNA through the nuclear membrane (see, for example, WO 93/18759) and membrane-permeabilizing compounds such as GALA, Gramicidine S, and cationic bile salts (see, for example, WO 93/19768).
  • Gold or tungsten microparticles can also be used for gene delivery, as described in WO 91/359, WO 93/17706, and Tang et al . (Nature 356:152, 1992).
  • the microparticle-coated nucleic acid molecules can be injected via intradermal or intraepidermal routes using needleless injection devices ("gene gun"), such as those described in U.S. Patent No. 4,945,050, U.S. Patent No. 5,015,580, and WO 94/24263.
  • the amount of artificial chromosome construct to be administered depends, e.g., on the specific goal to be achieved, the strength of any promoter used in the construct, the condition of the mammal intended for administration ( e . g ., the weight, age, and general health of the mammal), the mode of administration, and the type of formulation.
  • the administration can be achieved in a single dose or repeated at intervals.
  • the artificial chromosome constructs of the invention can be used to cheaply and efficiently produce recombinant viruses in vitro .
  • prior viral production methods have employed cosmid sets containing portions of viral genomes that are recombined to generate complete viral genomes upon introduction into cells. This method can result in instability of the viral genome.
  • the artificial chromosome constructs of the invention by-pass the need for recombination between multiple cosmids, leading to enhanced stability of the produced viral genome.
  • the artificial chromosome constructs of the invention such as those including BACs, can be propagated in host systems, such as bacteria, that are not adversely affected by the presence of viral genes that are harmful to mammalian cells. Standard methods can be used for introducing mutations into such constructs or for introducing heterologous genes to be included in a recombinant viral vector.
  • the artificial chromosome constructs of the invention also enable efficient packaging of amplicons into recombinant viral particles (see, e . g ., WO 97/05263).
  • Amplicons are plasmids containing a gene (e . g ., any of the heterologous nucleic acid sequences described above) under the control of regulatory sequences (e.g. , any of the promoters or enhancers described above and, optionally, sequences that direct processing of mRNA, such as a polyadenylation sequence), a viral origin of replication, and viral packaging signals.
  • an amplicon when an amplicon is co-transfected into a cell with an artificial chromosome construct of the invention, which includes viral DNA that results in recombinant virus formation upon introduction into a cell, the amplicon is packaged in a virion, thus providing an effective gene delivery vector.
  • Recombinant viruses produced using these methods can be used, for example, as viral vectors for therapy, e.g., gene therapy.
  • the artificial chromosome constructs of the invention can also be used in methods for generating cell lines that can be used, for example, for virus production.
  • an HSV-BAC construct can be made in which any one or any combination of the immediate early genes (i . e ., ICP0, ICP4, ICP22, ICP27, and ICP47) is mutated or deleted, using standard methods, such as those described above.
  • a gene encoding a selectable marker such as an antibiotic resistance gene (e.g. , a neomycin resistance gene) can be inserted into the viral genome in a non-essential region (see above) or into the BAC. This construct can then be transfected into cells (e.g.
  • Vero cells using standard methods, and clones containing integrated HSV can be selected by culturing the cells in the presence of, for example, the antibiotic.
  • Cells produced in this manner do not, without further manipulation, produce virus, due to the missing immediate early gene(s).
  • the cells can be cultured in the absence of the cytotoxicity that can be associated with viral production.
  • the missing immediate early gene(s) can be introduced into the cells by transfection.
  • BAC-TK Bacillus subtilis virus genome was constructed with viral tk sequences flanking the signals necessary for chromosomal maintenance in bacteria and the chloramphenicol resistance gene (Fig. 1). This plasmid was linearized and co-transfected with HSV-1 infectious DNA into Vero cells (ATCC CRL 1587). The resultant virus stocks were screened with 100 ⁇ M acyclovir (ACV), and resistant viruses were isolated and plaque purified. Southern blot and PCR analysis confirmed insertion of BAC and chloramphenicol sequences within the tk locus. The recombinant virus was designated HSV-BAC-TK.
  • Vero cells were infected for 2 hours with HSV-BAC-TK at an m.o.i. of 3, harvested, and DNA was extracted as is described below in Materials and Methods. Isolated circular DNA was electroporated into E. coli and recombinant colonies were screened for resistance to chloramphenicol. Bacteria that were resistant to the antibiotic were subjected to further analysis. Briefly, DNA was extracted from 11 colonies and subjected to PCR analysis using primer sets corresponding to HSV genes US6, UL10, UL30, and UL40. All I 1 clones tested were positive for all four primer sets. DNA was extracted from 8 of the 11 clones and digested with EcoRI, EcoRV, and HindIII. The results showed that the entire genome of HSV had been cloned.
  • the essential HSV gene, UL54 can be deleted as follows. (See Figs. 3A and 3B.)
  • the gene product of the UL54 gene, ICP27 plays many roles in HSV infection.
  • the protein, which is essential for viral growth, is found predominantly in the nucleus, where it inhibits pre-mRNA splicing, interacts with the host cell's small nuclear ribonucleoprotein particles, binds to RNA, prevents the nucleocytoplasmic transport of intron-containing mRNAs, and regulates late-gene protein synthesis by facilitating the export of late viral RNAs.
  • flanking sequences for homologous recombination two primer sets can be used. One set binds to a sequence that lies immediately upstream of the UL54 coding sequence and to a sequence about 1 kb upstream from this site, i.e ., in the UL53 gene. The second set binds to sequences immediately 3' of the UL54 stop codon and to a sequence about 1 kb downstream from this site, i.e. , in the UL55 gene. PCR fragments generated using these primers can be cloned into placi, generating p53-laci-55.
  • Kanamycin coding sequences can be amplified by PCR and cloned in frame with the ⁇ -complementation lacZ sequences of p53-placi-55 to create p53-laci-kan-UL55. Homologous recombination between this plasmid and BAC DNA results in replacement of the HSV UL54 coding sequences with the laci promoter driving the ⁇ -complementation lacZ /kanamycin fusion sequences.
  • p53-placi-kan-55 sequences can be released from the plasmid backbone, gel purified, and transformed into competent E. coli that contain p25. Recombinants can then be screened for their ability to grow on kanamycin, IPTG, and chloramphenicol plates. Southern hybridization can be used to confirm the presence of the mutation.
  • a clone having the correct mutation which could be designated p ⁇ UL54, could be further analyzed, as follows.
  • the growth kinetics of r ⁇ UL54, the rescued virus from p ⁇ UL54, r25, HSV-BAC-TK, and wild type HSV strain F could be compared in 2-2 and Vero cells.
  • 2-2 cells are a stable cell line that constitutively express ICP27, and thus are able to complement the UL54 defect. All four viruses would be expected to replicate to wild type levels in 2-2 cells, but rAUL54 would not be expected to grow on Vero cells.
  • Restriction endonuclease patterns of DNA extracted from the rescued mutant viruses or from input plasmid DNA could be carried out to confirm that BAC plasmids remain stable during the mutagenesis procedure.
  • HSV-BAC DNA packages amplicons
  • HSV-plasmid vectors contain a eukaryotic expression cassette and the HSV signals for replication and packaging.
  • the amplicon vector is replicated and packaged into virions when co-propagated with a helper virus, either wild type virus, replication-defective virus, or virus generated from HSV cosmids.
  • helper virus either wild type virus, replication-defective virus, or virus generated from HSV cosmids.
  • a modified cosmid set has been used to produce amplicon preparations that are free of contaminating helper virus (Fraefel et al., supra ).
  • herpes virus cosmids are prone to deletion and rearrangement and, further, are often heterogeneous in nature.
  • a BAC clone of HSV overcomes these problems.
  • coli containing BAC clones are homogeneous, while E. coli containing cosmid clones are heterogeneous in nature. Thus, maintenance of HSV sequences in BACs is preferable for the production of homogenous, infectious viral DNA for therapeutic purposes.
  • Trans functions were tested by determining the ability of HSV-BAC DNA to package amplicon plasmid DNA.
  • An amplicon plasmid containing the Green Fluorescent Protein (GFP) gene under the control of the IE 4/5 promoter, or an amplicon plasmid containing a lacZ gene under the control of the Rous Sarcoma Virus (RSV) promoter (pHSVLac) was co-propagated with either transfected p25, HSV cosmid DNA (6, 28, 14, 56, and 48; Cunningham et al., supra), or infectious F strain viral DNA (ATCC VR-733). Cells were .
  • HSV-BAC DNA could package amplicons more efficiently than cosmid DNA and infectious viral DNA.
  • Vero and Vero 2-2 cells were propagated and assayed for drug susceptibility as described by Coen et al . (Virology 168:221-231, 1989). Virus titers were determined in triplicate on Vero cells. Recombinant viruses were plaque-purified two times and the mutations were confirmed by Southern blot hybridization and PCR analysis.
  • Plasmid pTK-AB was created by subcloning the BglII/EcoRI fragment from pXhoIf (the XhoI F fragment of HSV-1 strain 17 cloned into plasmid pAT153) into the BamHI/EcoRI sites of pHSVlac (Geller et al., supra).
  • tk-containing plasmid BH13 (Horsburgh et al ., Cell 86(6):949-959, 1996) was digested with PstI and XhoI, to release the 3' end of the tk gene, and the fragment was subcloned into the PstI /XhoI site of pSC1180, creating plasmid TK-CD.
  • Plasmids TK-AB and TK-CD were digested with HindIII/MscI and HindIII/SalI, respectively, and the resulting fragments were subcloned into the HpaI/SalI sites of pBeloBAC (Dr. H. Shizuya and Dr. M. Simon, Department of Biology, California Institute of Technology, Pasadena, CA) to create plasmid pBAC-TK (Fig. 1).
  • pLaci was generated by digesting pBluescript KS (Stratagene) with SacI and NaeI, blunt ending with T4 DNA polymerase, and religating.
  • UL53, UL55, and kanamycin sequences were amplified by PCR using primers containing PvuII, HindIII, and KpnI/XhoI sites, respectively (Table 1).
  • the UL53 fragment was digested with PvuII and cloned into the unique PvuII site of pLaci, creating UL53-pLaci. The orientation of the fragment was confirmed by restriction enzyme digestion.
  • the UL55 fragment was digested with HindIII and cloned into the HindIII site of UL53-pLaci, creating UL53-pLaci-UL55.
  • the orientation was confirmed by restriction digestion.
  • the kanamycin fragment was digested with Kpnl and XhoI, and cloned into KpnI/XhoI-digested UL53-pLaci-UL54. This results in an in-frame fusion of lacZ ⁇ -complementation and kanamycin sequences.
  • This plasmid was called UL53-pLaci-kan-UL55.
  • pHSV-GFP Green Fluorescent Protein
  • PCR-amplified fragments were obtained using viral genomic DNA or plasmid DNA as template and the oligonucleotides listed in Table 1 as primers.
  • Taq DNA polymerase Promega was used to amplify the region of interest, according to the recommendations of Sambrook et al . (Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989) and 30 cycles (95 °C, 1 minute, 55°C, 1 minute, 72°C, 1 minute) were carried out in a Perkin Elmer GeneAmp 2400.
  • Plasmid BAC-TK was digested with HindIII and co-transfected into Vero cells with infectious HSV-1 F strain DNA, as described by Chiou et al . (Virology 145(2):213-226, 1985). DNA from plaques that were resistant to 100 ⁇ M acyclovir (ACV) was screened by PCR using primers that correspond to chloramphenicol sequences (Table 1). From each of two independent transfections, one recombinant virus was plaque-purified two times and the mutation confirmed by Southern blot hybridization. This virus was designated HSV-BAC.
  • BAC plasmids were isolated from E. coli using an alkaline-lysis procedure and screened by PCR. Four sets of primers were used to amplify sequences in US6, UL 10, UL30, and UL40 (Table 1). Two ⁇ g of DNA from clones that were positive for all primers sets was transfected into a 100 mm dish of Vero cells using 18 ⁇ l of lipofectamine, and incubated at 34°C. Viral plaques were observed two days post-transfection.
  • p25-containing bacteria were made competent by CaCl 2 treatment.
  • pUL53-pLaci-kan-UL55 was digested with XbaI, MluI, and ScaI, and the UL53-pLaci-kan-UL55 sequences were gel purified and transformed into competent p25 E. coli.
  • the bacteria were allowed to recover for 2 hours at 37°C in the presence of 1 mM IPTG, then plated out on kanamycin/IPTG plates (5 mg/ml and 1 mM, respectively). Mutations were confirmed by PCR and Southern blot hybridization. Mutant viruses were tested for growth on 2-2 and Vero cells.
  • 2-2 cells were transfected with 1, 2, or 4 ⁇ g of either p25, HSV cosmid set 6, 28, 14, 56, and 48 (Cunningham et al., supra), or infectious HSV F strain DNA and 1 g of pHSV-GFP, as described by Fraefel et al . (J. Virol. 70(10):7190-7197, 1996).
  • Cells were harvested after four days, frozen and thawed three times, the cellular debris was removed by centrifugation, and the supernatant was used to infect fresh monolayers. Titers were calculated by counting viral plaques and transduced green cells.
  • p25 BAC DNA see text for details; iDNA, infectious F strain HSV DNA; ⁇ a cosmids, HSV strain 17 cosmid set lacking "a" sites as described in Fraefel et al . ( supra ); wt cosmids, HSV strain 17 cosmid set as described in Cunningham et al . (supra).

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (13)

  1. Construction de chromosome artificiel comprenant des séquences de virus d'herpès simplex qui dirigent la formation d'un virus d'herpès simplex recombinant lors de l'introduction dans une cellule.
  2. Construction de chromosome artificiel selon la revendication 1, dans laquelle le virus recombinant est un virus lytique ou un virus non lytique.
  3. Construction de chromosome artificiel selon la revendication 1, dans laquelle le chromosome artificiel ou la séquence d'acide nucléique comprend, en outre, une séquence d'acide nucléique hétérologue, qui code de préférence un produit de gène thérapeutique, qui est de préférence choisi dans le groupe composé des facteurs de croissance, des hormones, des enzymes, des antigènes de vaccins, des cytotoxines, des protéines immunomodulatrices, des molécules d'ARN anti-sens et des ribosymes.
  4. Construction de chromosome artificiel selon la revendication 1, dans laquelle le chromosome artificiel est choisi dans le groupe composé des chromosomes artificiels de bactéries, des chromosomes artificiels dérivés du phage P1, des chromosomes artificiels de levure et des chromosomes artificiels de mammifères.
  5. Construction de chromosome artificiel selon la revendication 1, dans laquelle le virus recombinant est un virus Herpès simplex de type 1.
  6. Procédé in vitro de production d'un virus recombinant dans une cellule, le procédé comprenant l'introduction de la construction de chromosome artificiel selon la revendication 1 dans la cellule.
  7. Procédé selon la revendication 6, comprenant, en outre, l'introduction dans la cellule d'un amplicon qui est encapsidé dans un virion d'herpès simplex recombinant lors de l'introduction de la construction de chromosome artificiel dans la cellule, dans lequel ledit amplicon comprend une cassette d'expression eucaryote et des signaux d'herpès simplex pour la réplication et l'encapsidation.
  8. Procédé in vitro d'introduction d'une séquence d'acide nucléique hétérologue dans une cellule, le procédé comprenant l'introduction de la construction de chromosome artificiel selon la revendication 3 dans la cellule.
  9. Procédé in vitro permettant de tuer une cellule, le procédé comprenant l'introduction dans la cellule de la construction de chromosome artificiel selon la revendication 2, dans lequel le virus recombinant est un virus lytique et la cellule est, de préférence, une cellule cancéreuse.
  10. Cellule comprenant une construction de chromosome artificiel selon la revendication 1 intégrée de manière stable dans son génome.
  11. Cellule selon la revendication 10 dans laquelle ladite construction de chromosome artificiel comprend une séquence d'acide nucléique qui code un génome de virus d'herpès simplex dans lequel un gène précoce immédiat comprend une mutation.
  12. Utilisation de la construction de chromosome artificiel selon l'une quelconque des revendications 1 à 5 dans la fabrication d'un médicament pour produire un virus recombinant dans une cellule, pour introduire une séquence d'acide nucléique hétérologue dans une cellule, ou pour tuer une cellule.
  13. Utilisation selon la revendication 12, dans laquelle le virus recombinant est un virus lytique et la cellule est, de préférence, une cellule cancéreuse.
EP99902747A 1998-02-26 1999-01-29 Constructions de chromosomes artificiels, contenant des sequences d'acides nucleiques capables de diriger la formation d'un virus recombine Expired - Lifetime EP1056878B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31006 1998-02-26
US09/031,006 US6277621B1 (en) 1998-02-26 1998-02-26 Artificial chromosome constructs containing foreign nucleic acid sequences
PCT/IB1999/000285 WO1999043842A1 (fr) 1998-02-26 1999-01-29 Constructions de chromosomes artificiels, contenant des sequences d'acides nucleiques capables de diriger la formation d'un virus recombine

Publications (2)

Publication Number Publication Date
EP1056878A1 EP1056878A1 (fr) 2000-12-06
EP1056878B1 true EP1056878B1 (fr) 2006-08-02

Family

ID=21857171

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99902747A Expired - Lifetime EP1056878B1 (fr) 1998-02-26 1999-01-29 Constructions de chromosomes artificiels, contenant des sequences d'acides nucleiques capables de diriger la formation d'un virus recombine

Country Status (9)

Country Link
US (3) US6277621B1 (fr)
EP (1) EP1056878B1 (fr)
JP (1) JP2002504382A (fr)
AT (1) ATE335086T1 (fr)
AU (1) AU765521B2 (fr)
CA (1) CA2321964C (fr)
DE (1) DE69932599T2 (fr)
ES (1) ES2270580T3 (fr)
WO (1) WO1999043842A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19733364A1 (de) * 1997-08-01 1999-02-04 Koszinowski Ulrich H Prof Verfahren zur Klonierung eines großen Virusgenoms
US6277621B1 (en) * 1998-02-26 2001-08-21 Medigene, Inc. Artificial chromosome constructs containing foreign nucleic acid sequences
WO2000034497A2 (fr) * 1998-12-09 2000-06-15 The General Hospital Corporation Encapsidation amelioree d'amplicons de virus herpetique et production de vecteurs viraux recombines
US7196066B1 (en) * 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
ES2170622B1 (es) * 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
US6692954B1 (en) * 2000-11-03 2004-02-17 The Scripps Research Institute Generation of human cytomegalovirus yeast artificial chromosome recombinants
WO2002053576A1 (fr) * 2001-01-05 2002-07-11 The General Hospital Corporation Système viral de livraison pour le transfert infectieux de fragments d'insertion longs d'adn génomique
US20030059934A1 (en) * 2001-04-03 2003-03-27 Nikolaus Osterrieder Artificial chromosomes comprising EHV sequences
US7439346B2 (en) * 2001-10-12 2008-10-21 Perkinelmer Las Inc. Nucleic acids arrays and methods of use therefor
ES2208051B1 (es) * 2002-01-24 2005-08-16 Consejo Sup. Investig. Cientificas Secuencia de acido nucleico que comprende la señal de encapsidacion del rna de un coronavirus del grupo 1 y sus aplicaciones.
AR040601A1 (es) 2002-07-19 2005-04-13 Boehringer Ingelheim Vetmed Mutantes ehv negativos de gm sin elementos heterologos
US7335763B2 (en) * 2003-03-25 2008-02-26 University Of Florida Research Foundation, Inc. Herpesvirus ribozymes and vectors
WO2004087869A2 (fr) * 2003-03-25 2004-10-14 University Of Florida Ribozymes et vecteurs du virus de l'herpes
JP2007515947A (ja) * 2003-10-30 2007-06-21 タフツ−ニュー イングランド メディカル センター 羊水中の無細胞胎児ｄｎａを使用する出生前診断
CN1950507A (zh) * 2004-03-05 2007-04-18 财团法人阪大微生物病研究会 重组水痘－带状疱疹病毒
ES2679282T3 (es) 2004-10-22 2018-08-23 Revivicor Inc. Porcinos transgénicos que carecen de cadena ligera de inmunoglobulina endógena
EP2471936A3 (fr) * 2005-11-24 2013-04-24 The Research Foundation for Microbial Diseases of Osaka University Vaccin polyvalent recombiné
WO2007084767A2 (fr) * 2006-01-20 2007-07-26 University Of South Florida Procedes de profilage de transcriptosomes
WO2009051823A2 (fr) * 2007-10-18 2009-04-23 Michigan State University Chromosome bactérien artificiel contenant le génome du virus de l'herpès félin de type 1 et ses utilisations
JP5517116B2 (ja) * 2008-05-30 2014-06-11 国立大学法人 東京大学 組換えウイルス、これを保持する大腸菌およびその製造法
JPWO2010038904A1 (ja) * 2008-09-30 2012-03-01 国立大学法人鳥取大学 外来性核初期化因子またはそれをコードするｄｎａを含まない人工多能性幹細胞およびその作製方法
MX2011003535A (es) 2008-10-03 2011-09-21 Novartis Ag Composiciones de virus de herpes bovino-1, vacunas, y metodos.
ES2548377T3 (es) 2008-10-27 2015-10-16 Revivicor, Inc. Ungulados inmunodeprimidos
EP3380605A1 (fr) 2015-11-24 2018-10-03 GlaxoSmithKline Intellectual Property Development Limited Procédé de transfection transitoire pour la production de rétrovirus
GB201609354D0 (en) * 2016-05-26 2016-07-13 Glaxosmithkline Ip Dev Ltd Transient transfection method for retroviral production
CN115820571A (zh) * 2017-03-09 2023-03-21 厦门大学 一种重组单纯疱疹病毒及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
WO1990009441A1 (fr) 1989-02-01 1990-08-23 The General Hospital Corporation Vecteur d'expression du virus d'herpes simplex, type i
CA2039921A1 (fr) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfert et expression de la sequence d'adn dans les cellules du systeme nerveux central a l'aide de mutants du virus de l'herpes, avec deletions chez les genes en vue de repliquer le virus
US5658724A (en) 1992-07-31 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use
WO1995003400A1 (fr) 1993-07-23 1995-02-02 Johns Hopkins University School Of Medicine Clonage cible par recombinaison dans les chromosomes artificiels de levure
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
JPH11500014A (ja) 1995-02-21 1999-01-06 キャンタブ ファーマシューティカルズ リサーチ リミティド ウイルス調製物、ベクター、免疫原、及びワクチン
US5851826A (en) 1995-07-26 1998-12-22 Children's Medical Center Corporation Helper virus-free herpesvirus vector packaging system
US6133243A (en) 1996-02-22 2000-10-17 Onyx Pharmaceuticals, Inc. Liposomal-viral DNA complexes for treating disease
US6277621B1 (en) * 1998-02-26 2001-08-21 Medigene, Inc. Artificial chromosome constructs containing foreign nucleic acid sequences

Also Published As

Publication number Publication date
US6642207B1 (en) 2003-11-04
US6277621B1 (en) 2001-08-21
DE69932599T2 (de) 2007-09-27
ATE335086T1 (de) 2006-08-15
AU2294599A (en) 1999-09-15
CA2321964A1 (fr) 1999-09-02
JP2002504382A (ja) 2002-02-12
EP1056878A1 (fr) 2000-12-06
DE69932599D1 (de) 2006-09-14
ES2270580T3 (es) 2007-04-01
US20040171569A1 (en) 2004-09-02
WO1999043842A1 (fr) 1999-09-02
CA2321964C (fr) 2010-05-25
AU765521B2 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
EP1056878B1 (fr) Constructions de chromosomes artificiels, contenant des sequences d'acides nucleiques capables de diriger la formation d'un virus recombine
US8530437B2 (en) Methods for treating cancer using herpes simplex virus expressing antisense to the squamous cell carcinoma related oncogene
US6641817B1 (en) Herpes virus vectors for dendritic cells
US20070110720A1 (en) Vectors, mutant viruses and methods for generating mutant viruses
AU2018230046B2 (en) Recombinant Herpes simplex virus and use thereof
CA2196168A1 (fr) Vecteurs de virus de recombinaison
US20040063094A1 (en) Mutant herpes simplex viruses and uses thereof
Lilley et al. Herpes simplex virus vectors for the nervous system
EP1102858B1 (fr) Lignees cellulaires destinees a la propagation d'herpesvirus mutants
WO2005005637A2 (fr) Ciblage de virus sur des recepteurs de cellules de surface
MXPA00011346A (es) Virus del herpes simple mutantes, y usos de los mismos.
Kunec et al. An overlapping bacterial artificial chromosome system that generates vectorless progeny for channel catfish herpesvirus
US20040229362A1 (en) Method for producing non-pathogenic helper virus-free preparations of herpes virus amplicon vectors, the helper virus & the cells used in this method, the corresponding genetic tools, as well as the applications of these non-pathogenic amplicon vectors
AU2021322148A1 (en) Platform vector for modular and simplified insertion of transgenes into Alphaherpesvirinae
JP2004531254A (ja) Ｅｈｖ配列を含む人工染色体
Wussow Seamless manipulation of the varicella-zoster virus genome via bacterial artificial chromosome engineering
AU2129402A (en) Recombinant virus vectors
MXPA01001192A (en) Cell lines for the propagation of mutated herpes viruses

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000923

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MEDIGENE, INC.

17Q First examination report despatched

Effective date: 20030623

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MEDIGENE, INC.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

RIN1 Information on inventor provided before grant (corrected)

Inventor name: OSTROVE, JEFFREY

Inventor name: TUFARO, FRANCIS

Inventor name: QIANG, DONG

Inventor name: HORSBURGH, BRIAN

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060802

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060802

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20060802

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060802

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060802

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060802

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060802

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69932599

Country of ref document: DE

Date of ref document: 20060914

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061102

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061102

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070131

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2270580

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20070503

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070129

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061103

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070129

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060802

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20110309

Year of fee payment: 13

Ref country code: IT

Payment date: 20110228

Year of fee payment: 13

Ref country code: DE

Payment date: 20110127

Year of fee payment: 13

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20110519 AND 20110525

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 69932599

Country of ref document: DE

Owner name: CATHEREX, INC. (N.D.GES.D. STAATES DELAWARE), , US

Free format text: FORMER OWNER: MEDIGENE, INC., SAN DIEGO, CALIF., US

Effective date: 20110427

Ref country code: DE

Ref legal event code: R081

Ref document number: 69932599

Country of ref document: DE

Owner name: CATHEREX, INC. (N.D.GES.D. STAATES DELAWARE), US

Free format text: FORMER OWNER: MEDIGENE, INC., SAN DIEGO, US

Effective date: 20110427

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20110125

Year of fee payment: 13

Ref country code: ES

Payment date: 20110126

Year of fee payment: 13

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: CATHEREX INC.

Effective date: 20111020

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20120129

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20120928

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120129

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120801

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69932599

Country of ref document: DE

Effective date: 20120801

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120129

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120131

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20130708

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120130